Hemoglobin >= 9 g/dL, patients may receive transfusion to meet criterion within 30 days of day 1 of study
Hemoglobin > 9 g/dL, transfusion permitted
Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
Hemoglobin >= 8.0 g/dl (without transfusion within the previous 7 days)
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
Hemoglobin >= 10 g/dL without transfusion within 4 days prior to enrollment
Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days, =< 5 days prior to C1D1
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration.
Within 28 days prior to administration of study treatment: Hemoglobin >= 10 g/dL with no pack red blood cell transfusion in the past 28 days
Hemoglobin >= 8.0 g/dl, with or without transfusion
Hemoglobin 9 g/dl or more; (transfusion permitted)
Hemoglobin 9 g/dl or more; (transfusion permitted)
Hemoglobin >= 9g/dL (transfusion permitted)
Hemoglobin >= 9.0 g/dL (prior transfusion permitted) within 14 days of cycle 1 day 1
Hemoglobin >= 10.0 g/dL with no blood transfusion within 28 days of starting treatment
Hemoglobin >= 8 (with or without transfusion)
Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days, measured within 28 days prior to administration of study treatment
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin >= 10 g/dL (no blood transfusion in the 28 days prior to entry [olaparib guidelines])
Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
Hemoglobin >= 8.0 g/dL (transfusion permitted)
PHASE I: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
PHASE II SCLC: Hemoglobin >= 9 g/dl, and no blood transfusion within 4 weeks; OR > 10 g/dL, and no blood transfusion within 2 weeks
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollment
Hemoglobin >= 9 g/dL qualifications (transfusion permitted)
Hemoglobin >= 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
Hemoglobin greater than 8.0 g/dL (transfusion independent; no transfusion for >= 7 days prior to study enrollment)
Hemoglobin >= 9.0 mg/dL without transfusion in 2 prior weeks
Hemoglobin >= 8 g/dL (transfusion permitted)
Hemoglobin >= 9.0 g/dL (after transfusion if required)
Hemoglobin >= 9 g/dL; continuation of erythropoietin products is permitted; hemoglobin must be stable above 9 g/dL for at least 2 weeks without blood transfusion to maintain hemoglobin level
Hemoglobin ? 9 g/dL (without transfusion for at least one month)
Hemoglobin > 8.0 mg/dL (without transfusion in the preceding 7 days)
Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days.
Within 28 days prior to administration of study treatment: Hemoglobin ? 10.0 g/dL with no blood transfusion in the past 28 days
Within 14 days prior to first dose of study drug treatment: Hemoglobin >= 9 g/dL without transfusion in the previous week
Hemoglobin (no transfusion within prior 7 days) >= 9.0 g/dL
Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
Hemoglobin >= 10 g/dL with no blood transfusion in the past 28 days
Measured within 28 days prior to administration of study treatment: Hemoglobin >= 10.0 g/dL with no blood transfusion in the past 28 days
Within 28 days prior to administration of therapy: Hemoglobin >= 10 g/dL with no blood transfusion within 28 days of initiation of therapy
Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 days
Hemoglobin ?9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
Hemoglobin >10.5 g/dL (without erythropoietin or blood transfusion within the last 2 weeks)
Patients must have adequate organ and marrow function measured within 28 days prior to administration of ABT-888 as defined below:\r\n* >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
Hemoglobin >= 9 g/dL; erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks; hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1 of study drug without blood transfusion to maintain hemoglobin level
Hemoglobin >= 9 g/dL continuation of erythropoietin products is permitted obtained =< 7 days prior to randomization; hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level
Hemoglobin >= 9.0 g/dL (transfusion permitted)
Hemoglobin ? 8 g/dL (transfusion is permitted to fulfill this criterion)
Within 30 days prior to initiation of protocol treatment: Hemoglobin >= 9.0 g/dL (after transfusion if required)
Hemoglobin >= 8.0 g/dL with no blood transfusion in the past 28 days.
Hemoglobin > 9 g/dL (prior transfusion permitted)
Hemoglobin >= 9 g/dL (blood transfusion permitted to attain this value)
Measured within 28 days prior to administration of ABT-888: >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days
Hemoglobin >= 9 g/dl (transfusion permitted)
Hemoglobin >= 9 g/dL (without transfusion within 7 days of assessment)
Hemoglobin 9.0 g/dL (transfusion to meet this criterion is permitted)
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
Hemoglobin ? 9.0 g/dL (in case of transfusion stable for ?14 days prior to treatment start)
Hemoglobin ?8 g/dL [transfusion permitted]
Hemoglobin ?8 g/dL [transfusion permitted]
Hemoglobin >= 9 g/dL; subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL without transfusion within 1 week preceding study drug administration
Hemoglobin > 9.0 g/dL (no transfusion permitted within 1 week)
Hemoglobin >= 7g/dL (transfusion permitted)
Patients must have >= 10.0 g/dL hemoglobin (Hb) and no blood transfusion in the past 28 days to receive veliparib